Be the first to like this
Lothgren M, Bracco A, Lundkvist J, Biteeva I, Schwenkglenks M, Cristino J, Pereira J, Northridge K, Halperin M, Macarios D, Chung K, Danese MD. Cost-effectiveness of denosumab versus zoledronic acid (za) for the prevention of skeletal-related events (SRE) in patients with bone metastases (BM) from castration-resistant prostate cancer (CRPC) Sweden, Switzerland and Portugal. Presented at the 9th Annual HTAi meeting 2012 (Spain Bilbao 25-27 June 2012). Abstract published in Gaceta Sanitaria 2012, Vol. 26 Especial Congreso 2 – Junio 2012: 282.